Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-DLL3 CAR-NK cells SNC-115

A preparation of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), with potential immunomodulating and antineoplastic activities. Upon administration, anti-DLL3 CAR-NK cells SNC-115 recognize, bind to and induce selective cytotoxicity in DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-DLL3 CAR NK cells SNC-115 anti-DLL3 CAR-natural killer cells SNC-115
Code name:	SNC 115 SNC-115 SNC115

anti-DLL3 CAR-NK cells SNC-115

Search NCI's Drug Dictionary